Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-Genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response.
Phase of Trial: Phase IV
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OPTEX2-3
- 21 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Dec 2012 Planned End Date changed from 1 Aug 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned end date changed from 1 Jul 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.